

TEST REPORT

REPORT NO.: UG/2019/A1258A-01

Date: 2019/11/01

Page : 1 of 4



PROTERANN HEALTHCARE, INC.

3F., No. 94, Fuxing 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan(R.O.C.)

The following sample(s) was/were submitted and identified by/on behalf of client as:

Sample Name : Ultrasun Face SPF50+ 50ml
Applicant : PROTERANN HEALTHCARE, INC.
Address of Applicant : 3F., No. 94, Fuxing 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan(R.O.C.)
Tel No./Contact Person : 03-3183668 / PROTERANN HEALTHCARE, INC.
Packaging Condition : Please refer to the photo for sample shown at the last page of this report.
Quantity : 2pcs(158g)
Storage Condition : Room temperature
Item No. : ---
Lot/Batch No. : 44C0231-1
Manufacturer/Agent/Importer : Frike cosmetic AG
Date of Manufacturing : 2019.03
Date of Expiry : 2022.03
Importer: PROTERANN HEALTHCARE, INC.
Date of Sample Received : 2019/10/23
Date of Testing : 2019/10/23 ~ 2019/11/01

Test Results : -Please refer to next page(s)-

Shin Jyh Chen
Shin-Jyh Chen, Manager
Signed for and on behalf of
SGS Taiwan Ltd.



TEST REPORT

REPORT NO.: UG/2019/A1258A-01

Date: 2019/11/01

Page : 2 of 4



PROTERANN HEALTHCARE, INC.

3F., No. 94, Fuxing 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan(R.O.C.)

Test Results :

Test Item	CAS NO.	Test Method	Test Results	LOQ/LOD	Unit
#Preservatives(Paraben)	---	---	---	---	---
#Methyl paraben	000099-76-3	MOHW Suggestion Method-Method of Test for Preservatives in Cosmetics, 2014/08/12. Analysis was performed by HPLC/DAD	N.D.	0.0005	%
#Propyl paraben	000094-13-3		N.D.	0.0005	%
#Ethyl paraben	000120-47-8		N.D.	0.0005	%
#Butyl paraben	000094-26-8		N.D.	0.0005	%
#Isobutyl paraben	004247-02-3		N.D.	0.0005	%
#Isopropyl paraben	004191-72-5		N.D.	0.0005	%
#p-Hydroxybenzoic acid	000099-96-7		N.D.	0.002	%
#sec-Butyl paraben	017696-61-6		N.D.	0.0005	%
#Preservatives(Acid)	---	---	---	---	---
#Sorbic acid	000110-44-1	MOHW Suggestion Method-Method of Test for Preservatives in Cosmetics, 2014/08/12. Analysis was performed by HPLC/DAD	N.D.	0.002	%
#Dehydroacetic acid	000520-45-6		N.D.	0.002	%
#Benzoic acid	000065-85-0		N.D.	0.002	%
#p-Hydroxybenzoic acid	000099-96-7		N.D.	0.002	%
#Salicylic acid	000069-72-7		N.D.	0.002	%

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

TEST REPORT

REPORT NO.: UG/2019/A1258A-01

Date: 2019/11/01

Page : 3 of 4



PROTERANN HEALTHCARE, INC.

3F., No. 94, Fuxing 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan(R.O.C.)

Methylchloroisothiazolinone(MCI)	---	Method of Identification and Assay for Methylisothiazolinone and Methylchloroisothiazolinones in Cosmetics (Suggestion Method by MOHW, 2018/06/28). Analysis was performed by HPLC/DAD.	N.D.	0.00025	%
Methylisothiazolinone(MI)	---		N.D.	0.00025	%
MI/MCI(mixture)	---	MI+MCI	N.D.	---	%
Dimethicone	---	Analysis was performed by FTIR	Negative	---	---

NOTE :

- 1.The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
- 2.All items in this testing report is based on the request from client and we are responsible for that.
- 3.The content of this report is invalid if it is not presented as the entire report.
- 4.If the testing item belongs to quantitative analysis then this column describes Limit of Quantification(LOQ); If the testing item belongs to qualitative analysis then this column describes Limit of Detection(LOD).
- 5.The testing result will be "N.D." or "Negative" for the value less than LOQ/LOD, respectively.
- 6.The testing items having been accredited by MOHW are added with a mark "#".

- END -

TEST REPORT

REPORT NO.: UG/2019/A1258A-01

Date: 2019/11/01 Page : 4 of 4



PROTERANN HEALTHCARE, INC.

3F., No. 94, Fuxing 1st Rd., Guishan Dist., Taoyuan City 333, Taiwan(R.O.C.)

Sample Photo

UG/2019/A1258



UG/2019/A1258



UG/2019/A1258



UG/2019/A1258



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com/en/Terms-and-Conditions.aspx> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.